🔎 Trials Near Me

Utama › Kanser Paru-paru Bukan Sel Kecil › Virginia › Richmond

Kajian klinikal Kanser Paru-paru Bukan Sel Kecil di Richmond, VA

25 kajian untuk Kanser Paru-paru Bukan Sel Kecil sedang mencari peserta di lokasi dalam dan sekitar Richmond (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Mengambil pesertaFasa 3
  • Virginia Cancer Institute, Richmond
  • VCU Massey Cancer Center at Stony Point, Richmond
  • VCU Massey Comprehensive Cancer Center, Richmond
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Okt 2026 · NCT04267848

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Mengambil pesertaFasa 3
  • VCU Health Adult Outpatient Pavillion ( Site 0193), Richmond
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06623422

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Mengambil pesertaFasa 3
  • Virginia Cancer Institute, Richmond
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06498635

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Mengambil pesertaFasa 3
  • Local Institution - 0337, Richmond
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07361510

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Mengambil pesertaFasa 3
  • VCU Medical Center Gateway Building, Richmond
  • Virginia Commonwealth University, Richmond
  • VCU Health Short Pump Pavilion, Richmond
  • dan 4 lagi
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07144280

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

Mengambil pesertaFasa 1/2
  • VCU Medical Center Gateway Building, Richmond
  • Virginia Commonwealth University, Richmond
  • VCU Health Stony Point, Richmond
  • dan 2 lagi
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07227298

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Mengambil pesertaFasa 3
  • VCU Health Adult Outpatient Pavillion, Richmond
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06890598

Pan-tumor MRD Study

Mengambil pesertaKajian pemerhatian
  • Virginia Cancer Institute, Richmond
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06605404

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Mengambil pesertaFasa 3
  • Research Site, Richmond
  • Research Site, Midlothian · 11 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT06357533

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Mengambil pesertaFasa 2/3
  • VCU Massey Cancer Center, Richmond
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06712316

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Mengambil pesertaFasa 2/3
  • Virginia Commonwealth University (Vcu), Richmond
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07100080

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Mengambil pesertaFasa 3
  • Clinical Study Site, Richmond
  • Clinical Study Site, Richmond
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT06767514

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Mengambil pesertaFasa 2/3
  • Virginia Cancer Institute - West End, Richmond
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT04613596

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Mengambil pesertaFasa 3
  • VCU Health Adult Outpatient Pavillion, Richmond
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT06119581

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

Mengambil pesertaFasa 3
  • Research Site, Midlothian · 11 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 26 Ogo 2026 · NCT06350097

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

Mengambil pesertaFasa 3
  • VCU Massey Cancer Center at Stony Point, Richmond
  • VCU Massey Comprehensive Cancer Center, Richmond
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Jul 2026 · NCT06686771

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Mengambil pesertaFasa 2
  • VCU Medical Center (Virginia Commonwealth University), Richmond
Umur 18 hingga 70 · Semua jantina · Dikemas kini 26 Jun 2026 · NCT04614103

Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)

Mengambil pesertaFasa 2
  • Virginia Commonwealth University, Richmond
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Jun 2026 · NCT06731413

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Mengambil pesertaFasa 2
  • Virginia Cancer Institute, Richmond
  • VCU Massey Cancer Center at Stony Point, Richmond
  • VCU Massey Comprehensive Cancer Center, Richmond
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Mei 2026 · NCT06116682

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Mengambil pesertaFasa 2/3
  • Virginia Cancer Institute, Richmond
  • VCU Massey Cancer Center at Stony Point, Richmond
  • VCU Massey Comprehensive Cancer Center, Richmond
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Mei 2026 · NCT06616584

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

Mengambil pesertaFasa 2
  • Virginia Commonwealth University, Richmond
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Mei 2026 · NCT04317534

Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

Mengambil pesertaFasa 2
  • Virginia Commonwealth University, Richmond
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Apr 2026 · NCT06248606

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Mengambil pesertaKajian pemerhatian
  • VCU Massey Cancer Center at Stony Point, Richmond
  • Virginia Commonwealth University/Massey Cancer Center, Richmond
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Mac 2026 · NCT06418204

Repositioning Immunotherapy in VetArans With Lung Cancer

Mengambil pesertaFasa 2
  • Richmond VA Medical Center, Richmond, VA, Richmond
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Mac 2026 · NCT06275360

Kajian Kanser Paru-paru Bukan Sel Kecil di bandar lain

Kajian lain di Richmond

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.